19 September 2024 - Amplia Therapeutics  is pleased to announce that the US FDA has granted fast track designation to Amplia's focal adhesion kinase inhibitor, narmafotinib, for the treatment of advanced pancreatic cancer.

Amplia's clinical trial in advanced pancreatic cancer, the ACCENT trial, is on-going in Australia and South Korea.

Read Amplia Therapeutics press release